HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rash in patients receiving ticlopidine after intracoronary stent placement.

Abstract
As many as half of the approximately 400,000 patients who undergo nonsurgical coronary artery procedures every year receive an intracoronary stent. To prevent thrombus formation within the stent, antiplatelet treatment with ticlopidine and aspirin is administered. Ticlopidine is known to cause cutaneous adverse reactions in up to 5.1% of patients, with a 3.4% discontinuation rate. However, published studies of patients receiving the drug to prevent subacute thrombosis after intracoronary stent placement report a frequency of rash ranging from 0.8-1.6%. We hypothesized that the frequency of rash in this patient population is underreported, and conducted a retrospective chart review, collecting data on frequency and severity of rash, treatment required, patient demographics, and concomitant drugs that may predispose patients to rash. The frequency of rash was approximately 7% in this group of patients.
AuthorsT R Whetsel, D M Bell
JournalPharmacotherapy (Pharmacotherapy) Vol. 19 Issue 2 Pg. 228-31 (Feb 1999) ISSN: 0277-0008 [Print] United States
PMID10030774 (Publication Type: Journal Article)
Chemical References
  • Fibrinolytic Agents
  • Ticlopidine
Topics
  • Aged
  • Coronary Vessels (surgery)
  • Exanthema (chemically induced)
  • Female
  • Fibrinolytic Agents (adverse effects, therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Stents
  • Ticlopidine (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: